Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome: A Children's Cancer Group report

被引:36
作者
Lones, MA
Perkins, SL
Sposto, R
Tedeschi, N
Kadin, ME
Kjeldsberg, CR
Wilson, JF
Zwick, DL
Cairo, MS
机构
[1] Childrens Oncol Grp, Operat Ctr, Arcadia, CA 91066 USA
[2] Childrens Hosp Orange Cty, Dept Pathol, St Joseph Hosp, Orange, CA 92668 USA
[3] Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT USA
[4] Univ So Calif, Keck Sch Med, Los Angeles, CA USA
[5] Beth Israel Deaconess Hosp, Dept Pathol, Boston, MA USA
[6] Harvard Univ, Sch Med, Boston, MA 02115 USA
[7] Childrens Mercy Hosp, Dept Pathol, Kansas City, MO 64108 USA
[8] Columbia Univ, Div Pediat Oncol, Childrens Hosp New York, New York, NY USA
关键词
D O I
10.1200/JCO.2002.06.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose : Non-Hodgkin's lymphoma (NHL) arising in bone is a heterogeneous histologic type of NHL that includes large-cell lymphoma, lymphoblastic lymphoma, and small noncleaved-cell lymphoma. NHL arising in bone is well recognized in adults but is less well characterized and infrequent in children and adolescents. Patients and Methods., We performed a retrospective review of Children's Cancer Group (CCG) studies treating children and adolescents with NHL over a 20-year period (CCG-551, CCG-501, CCG-502, CCG-503, CCG-552, CCG-5911, and CCG-5941) and determined the response and event-free survival (EFS) rates in 31 patients with NHL arising in bone. Results: The patients ranged in age from 3 to 17 years (median, 11 years; mean, I I years), and 64.5% were male. All 31 (100%) patients achieved complete response. For 31 patients with NHL arising in bone, the product-limit estimated 5-year EFS was 83.8% +/- 6.7%. EFS in 17 patients with localized disease (Murphy stages I and 11) was 94.1% +/- 5.71%, and EFS in 14 patients with disseminated disease (Murphy stage 111) was 70.7% +/- 12.4% (log-rank P =.10). EFS in 17 patients treated with chemotherapy and radiation was 70.1% +/- 11.2%, and EFS in 14 patients treated with chemotherapy without radiation was 100% (P =.03). EFS in 26 patients with histology-directed treatment (LSA2-L2 or ADCOMP for lymphoblostic, other therapy for nonlymphoblastic) was 92.2% +/- 5.3%, and in five patients with non histology-directed treatment it was 40.0% +/- 21.9% (P <.001). Conclusion: NHL arising in bone is a heterogeneous type of NHL that makes up approximately 2.0% of NHL in children and adolescents on CCG studies. Response and survival in this young age group seem superb, with histology-directed treatment protocols without radiation in both localized and disseminated disease. (C) 2002 by American Society of Clinical Oncology.
引用
收藏
页码:2293 / 2301
页数:9
相关论文
共 54 条
[1]  
ABROMOWITCH M, 2000, P AN M AM SOC CLIN, V19, pA583
[2]   CHILDHOOD NON-HODGKINS LYMPHOMA - THE RESULTS OF A RANDOMIZED THERAPEUTIC TRIAL COMPARING A 4-DRUG REGIMEN (COMP) WITH A 10-DRUG REGIMEN (LSA2-L2) [J].
ANDERSON, JR ;
WILSON, JF ;
JENKIN, RDT ;
MEADOWS, AT ;
KERSEY, J ;
CHILCOTE, RR ;
COCCIA, P ;
EXELBY, P ;
KUSHNER, J ;
SIEGEL, S ;
HAMMOND, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 308 (10) :559-565
[3]   LONG-TERM FOLLOW-UP OF PATIENTS TREATED WITH COMP OR LSA2L2 THERAPY FOR CHILDHOOD NON-HODGKINS-LYMPHOMA - A REPORT OF CCG-551 FROM THE CHILDRENS CANCER GROUP [J].
ANDERSON, JR ;
JENKIN, RDT ;
WILSON, JF ;
KJELDSBERG, CR ;
SPOSTO, R ;
CHILCOTE, RR ;
COCCIA, PF ;
EXELBY, PR ;
SIEGEL, S ;
MEADOWS, AT ;
HAMMOND, GD .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (06) :1024-1032
[4]  
Antillon F, 1998, J PEDIAT HEMATOL ONC, V20, P552, DOI 10.1097/00043426-199811000-00010
[5]  
Baar J, 1999, SEMIN ONCOL, V26, P270
[6]  
BAAR J, 1994, CANCER, V73, P1194, DOI 10.1002/1097-0142(19940215)73:4<1194::AID-CNCR2820730412>3.0.CO
[7]  
2-R
[8]  
BACCI G, 1986, CANCER, V57, P1468, DOI 10.1002/1097-0142(19860415)57:8<1468::AID-CNCR2820570806>3.0.CO
[9]  
2-0
[10]  
CAIRO M, 1996, ANN ONCOL, V7, P29